A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
Completed · Phase 2 · Has a placebo group
Conditions studied: Thrombosis, Cancer, Pulmonary Embolism
In brief
The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic events. Demonstration of a favorable benefit:risk profile could lead to significant reduction in this serious and sometimes fatal complication of ongoing cancer and its treatment.
Key facts
- Study ID
- NCT00320255
- Run by
- Bristol-Myers Squibb
- People needed
- 130
- Starts
- 2006-06-01
- Expected to finish
- 2009-01-01
- Last updated by the study team
- 2016-08-16
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Cancer Center — Tucson, Arizona, United States
- Univ. Of Southern Calif. /Norris Comprehensive Cancer Center — Los Angeles, California, United States
- Dana-Farber Cancer Inst — Boston, Massachusetts, United States
- Nevada Cancer Institute — Las Vegas, Nevada, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- Mount Sinai School Of Medicine — New York, New York, United States
- University Of Rochester — Rochester, New York, United States
- University Of Texas Md Anderson Cancer Ctr — Houston, Texas, United States
- Local Institution — Hamilton, Ontario, Canada
- Local Institution — London, Ontario, Canada
- Local Institution — Toronto, Ontario, Canada
- Local Institution — Toronto, Ontario, Canada
- Local Institution — Montreal, Quebec, Canada
- Local Institution — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.